SecBot SecBot
SECBOTREPLAY Home › Report › OCGN

OCGN · Ocugen announced positive 12-month Phase 2 data for OCU410, its gene…

Ocugen · PRESS-RELEASE filed Mar 24, 2026 at 07:45 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 24, 2026 at 07:45 ET

Ocugen announced positive 12-month Phase 2 data for OCU410, its gene therapy for geographic atrophy (GA) secondary to dry AMD, showing a statistically significant 31% reduction in lesion growth versus control (p < 0.05) and strong safety with no serious adverse events. The company plans to initiate a Phase 3 trial in Q3 2026, positioning OCU410 as a potential one-time treatment addressing a major unmet need in a growing patient population.

  • OCU410 showed 31% reduction in GA lesion growth at 12 months (p < 0.05) in the optimal dose group
  • No OCU410-related serious adverse events or adverse events of special interest reported
  • 27% slower rate of ellipsoid zone (EZ) loss, indicating structural preservation of photoreceptors
  • 55% of treated patients achieved ≥30% lesion size reduction vs. control

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access